ABL Bio Inc
KOSDAQ:298380
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ABL Bio Inc
Total Equity
ABL Bio Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Total Equity
₩154.7B
|
CAGR 3-Years
31%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Total Equity
₩17.2T
|
CAGR 3-Years
61%
|
CAGR 5-Years
39%
|
CAGR 10-Years
27%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Total Equity
₩149.4B
|
CAGR 3-Years
31%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Total Equity
₩66.4B
|
CAGR 3-Years
113%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Equity
₩445.2B
|
CAGR 3-Years
44%
|
CAGR 5-Years
28%
|
CAGR 10-Years
28%
|
|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
Total Equity
₩70.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ABL Bio Inc
Glance View
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
See Also
What is ABL Bio Inc's Total Equity?
Total Equity
154.7B
KRW
Based on the financial report for Dec 31, 2025, ABL Bio Inc's Total Equity amounts to 154.7B KRW.
What is ABL Bio Inc's Total Equity growth rate?
Total Equity CAGR 5Y
11%
Over the last year, the Total Equity growth was -8%. The average annual Total Equity growth rates for ABL Bio Inc have been 31% over the past three years , 11% over the past five years .
